Patent intelligence · US
US 12264149
Indazole compounds as kinase inhibitors
Indazole compounds as kinase inhibitors
Patent details — US 12264149
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 1, 2025
- Expiration
- Mar 27, 2045
- Applicant
- TYRA BIOSCIENCES, INC.
- Claims
- 21
- CPC classes
- A61P, A61P35/00
Quick answer
US 12264149 (Indazole compounds as kinase inhibitors) is held by TYRA BIOSCIENCES, INC.. Status: granted. Granted Apr 1, 2025. Expires Mar 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TYRA BIOSCIENCES, INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61P, A61P35/00
More from TYRA BIOSCIENCES, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12290069
Pest control using natural pest control agent blends
granted -
US 12071428
Indazole compounds as kinase inhibitors
granted -
US 12035713
Pest control using natural pest control agent blends
granted -
US 11896007
Pest control using natural pest control agent blends
granted -
US 11116214
Lice control composition and method
granted -
US 10881104
Arthropod control composition, formulation, and method
granted -
US 10799472
Antiparasitic compositions and methods
granted
Frequently asked questions
What is US patent 12264149?
US 12264149 (Indazole compounds as kinase inhibitors) is held by TYRA BIOSCIENCES, INC.. Status: granted. Granted Apr 1, 2025. Expires Mar 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12264149?
TYRA BIOSCIENCES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 17 pharmaceutical patents for this assignee.
When does US 12264149 expire?
Our index shows an expiration date of Mar 27, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.